{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T18:12:11Z","timestamp":1790878331279,"version":"4.1.0"},"reference-count":53,"publisher":"Informa UK Limited","issue":"12","license":[{"start":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T00:00:00Z","timestamp":1704844800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.2217\/fon-2023-0774","type":"journal-article","created":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T05:26:56Z","timestamp":1704864416000},"page":"739-748","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":7,"title":["Xevinapant plus radiotherapy in resected, high-risk, cisplatin-ineligible LA SCCHN: the phase III XRay Vision study design"],"prefix":"10.1080","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6605-2071","authenticated-orcid":false,"given":"Robert L","family":"Ferris","sequence":"first","affiliation":[{"name":"University of Pittsburgh Medical Center","place":["Pittsburgh, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5544-6224","authenticated-orcid":false,"given":"Hisham","family":"Mehanna","sequence":"additional","affiliation":[{"name":"University of Birmingham","place":["Birmingham, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5119-0401","authenticated-orcid":false,"given":"Jonathan D","family":"Schoenfeld","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute","place":["Boston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9035-3106","authenticated-orcid":false,"given":"Makoto","family":"Tahara","sequence":"additional","affiliation":[{"name":"National Cancer Center Hospital East","place":["Kashiwa, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0779-7476","authenticated-orcid":false,"given":"Sue S","family":"Yom","sequence":"additional","affiliation":[{"name":"University of California San Francisco","place":["San Francisco, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1413-0079","authenticated-orcid":false,"given":"Robert","family":"Haddad","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute","place":["Boston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5976-7066","authenticated-orcid":false,"given":"Andr\u00e9","family":"K\u00f6nig","sequence":"additional","affiliation":[{"name":"Merck Healthcare KGaA","place":["Darmstadt, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Witzler","sequence":"additional","affiliation":[{"name":"Merck Healthcare KGaA","place":["Darmstadt, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcis","family":"Bajars","sequence":"additional","affiliation":[{"name":"Merck Healthcare KGaA","place":["Darmstadt, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9772-4686","authenticated-orcid":false,"given":"Christophe Le","family":"Tourneau","sequence":"additional","affiliation":[{"name":"Department of Drug Development and\u00a0Innovation (D3i), Institut Curie, Paris-Saclay University","place":["Paris, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,1,10]]},"reference":[{"key":"e_1_3_10_3_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"e_1_3_10_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu265"},{"key":"e_1_3_10_5_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2007-0157"},{"key":"e_1_3_10_6_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-07297-z"},{"issue":"7","key":"e_1_3_10_7_1","first-page":"Abstract 682P","article-title":"Patient characteristics and treatment patterns of newly diagnosed locally advanced head and neck squamous cell carcinoma (LA HNSCC): a retrospective cohort analysis of real-world data in England","volume":"33","author":"Kong A","year":"2022","unstructured":"Kong A , ChiuG , ShahSRet al. Patient characteristics and treatment patterns of newly diagnosed locally advanced head and neck squamous cell carcinoma (LA HNSCC): a retrospective cohort analysis of real-world data in England. Ann. Oncol.33(Suppl. 7), Abstract 682P (2022).","journal-title":"Ann. Oncol."},{"issue":"1","key":"e_1_3_10_8_1","first-page":"Abstract PCN351","article-title":"Real world evidence on patients characteristics and frontline treatment patterns in locally advanced squamous cell carcinoma of the head and neck from Europe and US","volume":"23","author":"Tarallo M","year":"2020","unstructured":"Tarallo M , PawarV , HallJet al. Real world evidence on patients characteristics and frontline treatment patterns in locally advanced squamous cell carcinoma of the head and neck from Europe and US. Value Health23(Suppl. 1), Abstract PCN351 (2020).","journal-title":"Value Health"},{"key":"e_1_3_10_9_1","unstructured":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Head and Neck Cancers V.1.2024. \u00a9 National Comprehensive Cancer Network Inc. (2023). All rights reserved. Accessed November 9 2023. To view the most recent and complete version of the guideline go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content use or application and disclaims any responsibility for their application or use in any way."},{"key":"e_1_3_10_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.07.011"},{"key":"e_1_3_10_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.prro.2017.02.002"},{"key":"e_1_3_10_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01293"},{"key":"e_1_3_10_13_1","unstructured":"Cisplatin. Prescribing information. WG Critical Care (2021). www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/018057s092lbl.pdf"},{"key":"e_1_3_10_14_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01522"},{"key":"e_1_3_10_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2015.11.019"},{"key":"e_1_3_10_16_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00464"},{"key":"e_1_3_10_17_1","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S322411"},{"key":"e_1_3_10_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.53.9163"},{"key":"e_1_3_10_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00980"},{"key":"e_1_3_10_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2015.03.001"},{"key":"e_1_3_10_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.24064"},{"key":"e_1_3_10_22_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13174363"},{"key":"e_1_3_10_23_1","doi-asserted-by":"publisher","DOI":"10.1042\/BJ20041800"},{"key":"e_1_3_10_24_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells9030663"},{"key":"e_1_3_10_25_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2014.00197"},{"key":"e_1_3_10_26_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells9041012"},{"key":"e_1_3_10_27_1","doi-asserted-by":"publisher","DOI":"10.2174\/156800908783769373"},{"key":"e_1_3_10_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3627"},{"key":"e_1_3_10_29_1","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S33375"},{"key":"e_1_3_10_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature14129"},{"key":"e_1_3_10_31_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14071671"},{"key":"e_1_3_10_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1203765"},{"key":"e_1_3_10_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.22554"},{"key":"e_1_3_10_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2009.03.002"},{"key":"e_1_3_10_35_1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nor066"},{"key":"e_1_3_10_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2004.11.049"},{"key":"e_1_3_10_37_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0031601"},{"key":"e_1_3_10_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2011.387"},{"key":"e_1_3_10_39_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-12-0167"},{"key":"e_1_3_10_40_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2014-2752"},{"issue":"3","key":"e_1_3_10_41_1","first-page":"640","article-title":"IAP-1 promoted cisplatin resistance in nasopharyngeal carcinoma via inhibition of caspase-3-mediated apoptosis","volume":"11","author":"Miao X","year":"2021","unstructured":"Miao X , DengZ , WangSet al. IAP-1 promoted cisplatin resistance in nasopharyngeal carcinoma via inhibition of caspase-3-mediated apoptosis. Am. J. Cancer Res.11(3), 640\u2013667 (2021).","journal-title":"Am. J. Cancer Res."},{"key":"e_1_3_10_42_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm101505d"},{"key":"e_1_3_10_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2015.05.017"},{"key":"e_1_3_10_44_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-35860-z"},{"key":"e_1_3_10_45_1","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.20563"},{"key":"e_1_3_10_46_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20101123"},{"key":"e_1_3_10_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13002"},{"key":"e_1_3_10_48_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-020-00312-6"},{"key":"e_1_3_10_49_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2021-1634"},{"key":"e_1_3_10_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30327-2"},{"key":"e_1_3_10_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2022.12.015"},{"key":"e_1_3_10_52_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2013-2055"},{"key":"e_1_3_10_53_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.6027"},{"key":"e_1_3_10_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70023-3"},{"issue":"16","key":"e_1_3_10_55_1","first-page":"Abstract TPS610","article-title":"XRay Vision: a phase 3study of xevinapant plus radiotherapy (RT) for high-risk, cisplatin-ineligible patients with resected, locally advanced squamous cell carcinoma of the head and neck (LA SCCHN)","volume":"41","author":"Ferris RL","year":"2023","unstructured":"Ferris RL , MehannaHM , SchoenfeldJDet al. XRay Vision: a phase 3study of xevinapant plus radiotherapy (RT) for high-risk, cisplatin-ineligible patients with resected, locally advanced squamous cell carcinoma of the head and neck (LA SCCHN). J. Clin. Oncol.41(Suppl. 16), Abstract TPS6101 (2023).","journal-title":"J. Clin. Oncol."}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2023-0774","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T14:56:58Z","timestamp":1762181818000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2023-0774"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,10]]},"references-count":53,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["10.2217\/fon-2023-0774"],"URL":"https:\/\/doi.org\/10.2217\/fon-2023-0774","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,10]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-09-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-11-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}